Opko Health, Inc. · NASDAQ:OPK
Opko Health — Shareholder Meeting (June 2017)
32 slides from Opko Health's shareholder meeting presentation, Jun 15, 2017
Slide 1: OPKO Health, Inc. Annual Shareholders Meeting June 15, 2017
Opko health, Inc. Annual shareholders meeting June 15, 2017 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “est
Slide 3: Rayaldee sends a clear message
Rayaldee sends A clear message:
Slide 4: Adoption of Rayaldee is Steadily Expanding
Adoption of Rayaldee is Steadily Expanding Source: IMS Data
Slide 5: Patient Access to Rayaldee is Steadily Expanding
Patient ACCESS to Rayaldee is STEADILY Expanding
Slide 6: Sales and Medical Forces are expanding
Sales and Medical Forces are expanding Our field sales force at launch (35 Reps and 5 Regional Managers) was sized significantly smaller than most competitive field forces in nephrology. Our field medical force at launch (12 MSLs) was sized significantly smaller than most competitive medical forces
Slide 7: Updated clinical practice guideline expected this month
Updated clinical practice guideline expected this month Updated KDIGO guideline for CKD-Mineral and Bone Disorder is expected to be available online in June, and published shortly afterwards in Kidney International. Under the draft guideline: Calcitriol and its 1α-hydroxylated vitamin D analogs are
Slide 8: Rayaldee license with Vifor Fresenius joint venture
RAYALDEE license with vifor Fresenius joint venture Terms of global collaboration with Vifor Fresenius Medical Care Renal Pharma (VFMCRP): Up to $282 million in upfront and milestone payments to OPKO ($50M to date) Up to $555 million more if VFMCRP exercises option for U.S. dialysis market Double di
Slide 9: Additional progress on Rayaldee
Additional progress on Rayaldee New Drug Submission (NDS) filed in Canada in May 2017 Phase 2 trial in hemodialysis patients targeted to start in Q4 2017 Licensing efforts for other ex-US territories ongoing Marketing Authorization Application (MAA) in EU targeted for H1 2018
Slide 10: Strong Growth – Build Further Momentum
Strong Growth – Build Further Momentum Specialized sales force for Urology Sales incentive program TV advertisement in Northeast Expanded coverage 107% growth
Slide 11: 4Kscore Marketing Update
Medicare and all large national payers providing good coverage Strong scientific and commercial presence at AUA (Boston, May 2017) VA clinical trial à VA formulary Study to address Palmetto LCD issue underway NCCN Guidelines update: positive for 4Kscore and Prostate Cancer Hereditary Panel testing 4
Slide 12: CLAROS Update
PSA clinical trial data collection closing in early July PMA preparation underway Testosterone assay meets performance goals and in final stages of development 510(k) filing in 1Q2018 CLAROS UPDATE
Slide 13: hGH-CTP Program Status
hGH-CTP PROGRAM STATUSPROGRAM STATUS Initiated Phase 3 pediatric hGH-CTP study in December 2016 220 patients, non-inferiority comparison of weekly hGH-CTP to daily growth hormone Global study CROs selected; sites initiated in December Easy-to-use, disposable, refrigerated pen device Phase 3 adult hG
Slide 14: Pen Injection Device for Growth Hormone
PEN INJECTION DEVICE FOR GROWTH HORMONE
Slide 15: OPK-88004 SARM for the Treatment of BPH
OPK-88004 SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) FOR THE TREATMENT OF BPH ANABOLIC EFFECTS Lean body mass Muscle power Fat mass ANTAGONISTIC EFFECTS PSA (PSA ≥ 3 ng/mL at baseline) Change from baseline (gm) Change from baseline (Watts) Change from baseline (gm) Change from baseline (gm) Tadala
Slide 16: OPK-88004 Phase 2b Study and Other Potential Indications
OPK-88004 SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) FOR THE TREATMENT OF BPH Once-a-day Dosing in Men with Signs and Symptoms of Benign Prostatic Hyperplasia 100 naïve BPH patients Expected to start in 2H 2017 OPK-88004 PHASE 2b CLINICAL STUDY (SAR 202) Urinary stress incontinence Bladder leakage
Slide 17: OPK-88003 Oxyntomodulin Analog for Type 2 Diabetes and Obesity
26 million diabetics in US: drug development focused on: blood glucose control and reducing body weight OPK-88003 is an once-weekly analog with both GLP-1 and glucagon activity Data support that combining GLP-1 and glucagon activity provides superior weight loss Data from phase 2 study in 420 type 2
Slide 18: OPK-88002 NK Antagonist for Pruritus in Dialysis Patients
OPK-88002 NK 1 ANTAGONIST FOR THE TREATMENT OF PRURITUS IN DIALYSIS PATIENTS Major medical need and requires management 70 to 90% of patients Kidney dialysis patients suffer from Pruritus PRURITUS IN DIALYSIS PATIENTS Expected to begin in 2H 2017 PHASE 2a CLNICAL STUDY Acute and chronic pruritus (“i
Slide 19: BioReference Laboratories
OPKO Shareholders Presentation June 15th, 2017 BioReference Laboratories
Slide 20: The Vision, The Metric, The Focus
The Vision… We will be the premium provider of laboratory medicine and pathology consultation services and the definitive leader in diagnostic innovations. The Metric… We will be the laboratory that physicians, healthcare systems, and patients request for their testing and diagnosis. The Focus… Part
Slide 21: Tectonic Shifts In The Healthcare Ecosystem
Tectonic Shifts In The Healthcare Ecosystem In Recent Years Consolidation and Integration Move from reimbursement by volume of care to risk-based, metric-driven ”value” of care Why? It’s the right thing to do. The economic ecosystem is finally aligning with the right thing to do. The pace of transit
Slide 22: Company Highlights
Company Highlights Third largest clinical lab in USA Receives specimens from 40,000 patient per day Accounts in all 50 states 300 Patient Service Centers and 600 In-Office Phlebotomists Central laboratory in Elmwood Park, NJ GeneDx laboratory in Gaithersburg, MD Satellite clinical laboratories: Camp
Slide 23: Buss * HO
Buss * HO tenon Ot BioReference LABORATOR! 2 OPKO Health Compant > > > - « * . > >». Re bs “4 oe »
Slide 24: Key Assets – BRLI and GeneDx
Key Assets – BRLI Complete portfolio of testing from routine to esoteric 42 board-certified, subspecialty trained pathologists 30 years of patient data, highly diverse and longitudinal Key Assets – GeneDx Premium brand in germline genomic testing – “the doctor’s doctor” Over 100 MD and PhD specialis
Slide 25: BioReference Laboratories business units
Laboratorio Buena Salud BioReference Laboratories Clinical Laboratory GenPath Women’s Health GenPath Oncology GeneDx
Slide 26: Company Challenges and Solutions
BioReference Laboratories Company Challenges and Solutions New Leadership To Execute On New Vision Dr. Ben Solomon - Director of GeneDx John Mooney - CIO Aging Enterprise Systems Migration to Xifin billing system - 10/1/17 Deployment of SAP for accounting and enterprise resource management - 10/1/17
Slide 27: Divisional Challenges
Clinical Laboratory Value based payment systems Continued price compression PAMA Divisional Challenges GenPath Women’s Health Major changes in clinical guidelines for testing Pap Testing every 3 years GenPath Oncology Consolidation of oncology practices into integrated healthcare systems Requires IT
Slide 28: The Strategy - Collaborative Partnerships
The Strategy - Collaborative Partnerships Hospital Systems Lead with GeneDx Northwell Joint Venture University of California - Exclusive Contract Vanderbilt University 4K Score Kaiser Permanente Adoption by integrated healthcare systems Key Opinion Leader Support Opens the door to the remainder of t
Slide 29: It's All About The Data
It’s All About The Data Patient-Centric Integration Improvement in Revenue Collection Machine Learning/Artificial Intelligence for Clinical Predictive Analytics Clinical Testing Decision Support
Slide 30: BioReference - our focus
BioReference - our focus Profitability and cash flow Improve profitability and cash flow through a revenue cycle management program Focus on operational effectiveness to meaningfully reduce costs Target improved profit margins during 2017 Grow profit in 2018 and beyond to be in line with the industr
Slide 31: Historical growth and profitability
Historical growth and profitability (in 000’s) As a result of the acquisition, 2015 is not comparable and therefore is not reflected in the table or chart. Fiscal Year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Net Revenues ,163,896 ,193,134 ,250,431 ,301,071 ,362,654 ,458,024 ,522,
Slide 32: Historical Cash Flows
Historical Cash Flows (in 000’s) Period Operating Cash Flows Capital Expenditures Free Cash Flows 2005 2,899 2,860 39 2006 5,200 2,859 2,341 2007 5,897 7,745 -1,848 2008 18,876 7,824 11,052 2009 24,366 8,749 15,617 2010 13,405 16,494 -3,089 2011 30,946 14,117 16,829 2012 53,098 15,715 37,383 2013 17